Drug name - Alunbrig

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Jul, 2030

(7 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(13 years from now)

CN102105150A TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

CN102105150B TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

CN107108559B TAKEDA PHARMS USA 5 - -N4-(2 -) (Dimethyl Phosphoryl) Phenyl] -N2-(2 - -4-(4 - (4 --- Yl)--- Piperazin - -1 - Piperidin - -1 - Yl] - Phenyl) - Pyrimidine - -2, 4 - - Diamine Crystalline Form
Oct, 2035

(13 years from now)

CN107108559A TAKEDA PHARMS USA 5 - -N4-(2 - (- Dimethyl) Phenyl] -N2-(2-Methoxy - -4-[4 - (4-Methylpiperazine - -1 - Yl)--1 - Group]--2, 4-Diamine In Crystalline Form
Oct, 2035

(13 years from now)

EP2300013A1 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP2300013A4 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP2300013B1 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP3209647B1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

EP3209647A1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors May, 2029

(6 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers Apr, 2034

(11 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.